Faith E Davies

List of Publications by Citations

185 papers	8,847 citations	41 h-index	93 g-index
195 ext. papers	10,433 ext. citations	5.1 avg, IF	5.67 L-index

#	Paper	IF	Citations
185	High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. *New England Journal of Medicine*, **2003**, 348, 1875-83	59.2	1469
184	Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. *Blood*, **2001**, 98, 210-6	2.2	773
183	The genetic architecture of multiple myeloma. *Nature Reviews Cancer*, **2012**, 12, 335-48	31.3	607
182	Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. *Journal of Clinical Oncology*, **2015**, 33, 3911-20	2.2	348
181	Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. *Journal of Clinical Oncology*, **2005**, 23, 9219-26	2.2	326
180	Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. *Journal of Clinical Oncology*, **2013**, 31, 2540-7	2.2	313
179	The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. *Blood*, **2012**, 119, 7-15	2.2	270
178	A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. *Blood*, **2010**, 116, e56-65	2.2	263
177	Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. *Leukemia*, **2014**, 28, 384-390	10.7	202
176	Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. *Blood*, **2007**, 110, 2641-9	2.2	200
175	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. *Blood*, **2018**, 132, 587-597	2.2	196
174	Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. *Blood*, **2011**, 117, 553-62	2.2	182
173	APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. *Nature Communications*, **2015**, 6, 6997	17.4	176
172	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. *Leukemia*, **2019**, 33, 159-170	10.7	176
171	Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. *Blood*, **2011**, 118, 1231-8	2.2	163
170	Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 57-73	21.7	154
169	Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. *Blood*, **2016**, 128, 1735-44	2.2	129

168	Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. *Blood*, **2013**, 122, 219-26	2.2	128
167	Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. *Blood*, **2015**, 125, 1932-5	2.2	128
166	Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. *Haematologica*, **2012**, 97, 442-50	6.6	121
165	Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. *Clinical Cancer Research*, **2013**, 19, 6030-8	12.9	116
164	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. *Nature Communications*, **2016**, 7, 12050	17.4	101
163	Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. *Blood*, **2013**, 121, 3413-9	2.2	101
162	XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. *Blood*, **2010**, 116, 250-3	2.2	92
161	Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. *British Journal of Haematology*, **2007**, 137, 268-9	4.5	86
160	Lenalidomide mode of action: linking bench and clinical findings. *Blood Reviews*, **2010**, 24 Suppl 1, S13-9	11.1	85
159	European perspective on multiple myeloma treatment strategies in 2014. *Oncologist*, **2014**, 19, 829-44	5.7	77
158	Toward personalized treatment in multiple myeloma based on molecular characteristics. *Blood*, **2019**, 133, 660-675	2.2	68
157	Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. *Cell Chemical Biology*, **2017**, 24, 371-380	8.2	66
156	The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. *Haematologica*, **2007**, 92, 1149-50	6.6	62
155	Assessment of Total Lesion Glycolysis by F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. *Clinical Cancer Research*, **2017**, 23, 1981-1987	12.9	57
154	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. *Nature Communications*, **2018**, 9, 3707	17.4	57
153	The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. *Clinical Cancer Research*, **2016**, 22, 5783-5794	12.9	56
152	DangER: protein ovERload. Targeting protein degradation to treat myeloma. *Haematologica*, **2012**, 97, 1119-30	6.6	56
151	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. *Clinical Cancer Research*, **2017**, 23, 3980-3993	12.9	51

150	Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. *Blood*, **2014**, 123, 3414-9	2.2	51
149	Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. *JAMA Oncology*, **2018**, 4, 1389-1397	13.4	48
148	Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. *Blood*, **2014**, 124, 2467-8	2.2	45
147	The level of deletion 17p and bi-allelic inactivation of has a significant impact on clinical outcome in multiple myeloma. *Haematologica*, **2017**, 102, e364-e367	6.6	44
146	A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. *Lancet Haematology,the*, **2019**, 6, e154-e166	14.6	44
145	The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. *Haematologica*, **2017**, 102, 1617-1625	6.6	42
144	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. *Haematologica*, **2019**, 104, 1440-1450	6.6	39
143	Cleavage of BLOC1S1 mRNA by IRE1 Is Sequence Specific, Temporally Separate from XBP1 Splicing, and Dispensable for Cell Viability under Acute Endoplasmic Reticulum Stress. *Molecular and Cellular Biology*, **2015**, 35, 2186-202	4.8	39
142	The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. *Leukemia and Lymphoma*, **2006**, 47, 2335-8	1.9	38
141	MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. *Blood*, **2016**, 128, 2919-2930	2.2	36
140	Update on the optimal use of bortezomib in the treatment of multiple myeloma. *Cancer Management and Research*, **2017**, 9, 51-63	3.6	34
139	Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1703-7	4	33
138	Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen. *Haematologica*, **2016**, 101, e69-71	6.6	33
137	Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. *Blood*, **2015**, 125, 3756-9	2.2	31
136	Long-term outcomes after autologous stem cell transplantation for multiple myeloma. *Blood Advances*, **2020**, 4, 422-431	7.8	30
135	Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?. *Leukemia*, **2018**, 32, 1561-1566	10.7	29
134	Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. *Haematologica*, **2018**, 103, 1047-1053	6.6	29
133	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. *Blood Cancer Discovery*, **2020**, 1, 234-243	7	29

132	Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. *Leukemia*, **2018**, 32, 1727-1738	10.7	27
131	Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. *Lancet Haematology,the*, **2019**, 6, e616-e629	14.6	26
130	A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. *Genes Chromosomes and Cancer*, **2015**, 54, 91-8	5	26
129	Immunologic approaches for the treatment of multiple myeloma. *Cancer Treatment Reviews*, **2017**, 55, 190-199	14.4	25
128	Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study. *Blood*, **2016**, 128, 1143-1143	2.2	23
127	Microhomology-mediated end joining drives complex rearrangements and overexpression of and in multiple myeloma. *Haematologica*, **2020**, 105, 1055-1066	6.6	22
126	The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. *Haematologica*, **2017**, 102, e313-e316	6.6	21
125	Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. *American Journal of Hematology*, **2017**, 92, 739-745	7.1	21
124	Subclonal copy number is associated with prognosis in multiple myeloma. *Blood*, **2018**, 132, 2465-2469	2.2	21
123	Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. *Blood*, **2000**, 96, 2943-2950	2.2	20
122	The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. *Nature Communications*, **2021**, 12, 293	17.4	20
121	The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. *Oncotarget*, **2017**, 8, 27854-27867	3.3	19
120	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. *Blood Cancer Journal*, **2018**, 9, 1	7	18
119	and Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 2422-2432	12.9	17
118	The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma. *Clinical Cancer Research*, **2018**, 24, 2913-2919	12.9	17
117	An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome. *Blood Cancer Journal*, **2019**, 9, 62	7	17
116	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. *Blood Cancer Journal*, **2020**, 10, 70	7	16
115	Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. *Scientific Reports*, **2015**, 5, 12473	4.9	16

114	Kinase domain activation through gene rearrangement in multiple myeloma. *Leukemia*, **2018**, 32, 2435-2444	10.7	15
113	Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. *BMC Nephrology*, **2018**, 19, 178	2.7	14
112	Neutral tumor evolution in myeloma is associated with poor prognosis. *Blood*, **2017**, 130, 1639-1643	2.2	14
111	Understanding the molecular biology of myeloma and its therapeutic implications. *Expert Review of Hematology*, **2012**, 5, 603-17	2.8	14
110	MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma. *BMC Cancer*, **2018**, 18, 724	4.8	13
109	Is molecular remission the goal of multiple myeloma therapy?. *Hematology American Society of Hematology Education Program*, **2017**, 2017, 205-211	3.1	13
108	The role of next generation sequencing in infection prevention in human parainfluenza virus 3 infections in immunocompromised patients. *Journal of Clinical Virology*, **2017**, 92, 53-55	14.5	12
107	Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results. *Blood*, **2010**, 116, 623-623	2.2	11
106	Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes. *British Journal of Haematology*, **2019**, 184, 578-593	4.5	11
105	Lenalidomide induction and maintenance therapy for transplant eligible myeloma patients: Results of the Myeloma XI study.. *Journal of Clinical Oncology*, **2017**, 35, 8009-8009	2.2	10
104	Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. *PLoS Medicine*, **2020**, 17, e1003323	11.6	10
103	The genomic landscape of plasma cells in systemic light chain amyloidosis. *Blood*, **2018**, 132, 2775-2777	2.2	10
102	Search for rare protein altering variants influencing susceptibility to multiple myeloma. *Oncotarget*, **2017**, 8, 36203-36210	3.3	9
101	Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation. *Blood*, **2016**, 128, 4516-4516	2.2	8
100	The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. *Journal of Hematology and Oncology*, **2020**, 13, 108	22.4	8
99	Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?. *Theranostics*, **2019**, 9, 4756-4763	12.1	7
98	Response Adapted Induction Treatment Improves Outcomes for Myeloma Patients; Results of the Phase III Myeloma XI Study. *Blood*, **2016**, 128, 244-244	2.2	7
97	The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse. *Blood*, **2016**, 128, 4431-4431	2.2	7

96	The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFB signalling pathway. *Oncotarget*, **2015**, 6, 17314-27	3.3	7
95	Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. *Haematologica*, **2021**, 106, 1957-1967	6.6	6
94	Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study. *Blood*, **2017**, 130, 835-835	2.2	6
93	How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. *Blood Cancer Discovery*, **2021**, 2, 562-567	7	6
92	Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma. *Journal of Bone and Mineral Research*, **2017**, 32, 1261-1266	6.3	5
91	Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes. *Human Genomics*, **2019**, 13, 37	6.8	5
90	Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of. *Oncotarget*, **2019**, 10, 732-737	3.3	5
89	COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers **2020**,		5
88	Sequential minimal residual disease (MRD) monitoring: Results from the UK Myeloma XI trial. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e45-e46	2	5
87	Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. *British Journal of Haematology*, **2021**, 192, 853-868	4.5	5
86	Practical Considerations for Antibodies in Myeloma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2018**, 38, 667-674	7.1	5
85	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.. *Journal of Clinical Oncology*, **2022**, JCO2102228	2.2	5
84	Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?. *Immunotherapy*, **2016**, 8, 367-84	3.8	4
83	Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma. *Blood*, **2014**, 124, 4775-4775	2.2	4
82	High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance. *Blood*, **2015**, 126, 20-20	2.2	4
81	A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex. *PLoS ONE*, **2014**, 9, e99493	3.7	4
80	Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. *PLoS Medicine*, **2021**, 18, e1003454	11.6	4
79	Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms. *Blood*, **2019**, 134, 3767-3767	2.2	3

78	The Value Of Serum Free Light Chain Monitoring Compared To Urinary Bence-Jones Measurement In Light Chain Only Myeloma. *Blood*, **2013**, 122, 1895-1895	2.2	3
77	A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial. *Blood*, **2016**, 128, 3321-3321	2.2	3
76	Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. *Leukemia*, **2021**,	10.7	3
75	A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. *Blood Advances*, **2018**, 2, 2400-2411	7.8	3
74	Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. *Leukemia*, **2021**,	10.7	3
73	Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. *Blood*, **2015**, 126, 2979-2979	2.2	2
72	The Co-Occurrence of MAF Translocations in RAS Mutated Multiple Myeloma Confers Resistance to MEK Inhibition. *Blood*, **2016**, 128, 1138-1138	2.2	2
71	Primary IMiD Refractory Myeloma; Results from 3894 Patients Treated in the Phase III Myeloma XI Study. *Blood*, **2016**, 128, 1144-1144	2.2	2
70	Extensive Regional Intra-Clonal Heterogeneity in Multiple Myeloma - Implications for Diagnostics, Risk Stratification and Targeted Treatment. *Blood*, **2016**, 128, 3278-3278	2.2	2
69	Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients. *Blood*, **2016**, 128, 3304-3304	2.2	2
68	Identifying Ultra-High Risk Myeloma By Integrated Molecular Genetic and Gene Expression Profiling. *Blood*, **2016**, 128, 4407-4407	2.2	2
67	The Impact of Maintenance Lenalidomide on the Mutational Status of the Myeloma Clone at Relapse in the NCRI Myeloma XI Trial for Newly Diagnosed Multiple Myeloma Patients (NDMM). *Blood*, **2016**, 128, 4412-4412	2.2	2
66	MYC Rearrangements in Multiple Myeloma Are Complex, Can Involve More Than Five Different Chromosomes, and Correlate with Increased Expression of MYC and a Distinct Downstream Gene Expression Pattern. *Blood*, **2017**, 130, 65-65	2.2	2
65	Translocations and Jumping Rearrangements at 8q24 Result in over-Expression of MYC and are Key Drivers of Disease Progression. *Blood*, **2016**, 128, 115-115	2.2	2
64	Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. *Blood Advances*, **2020**, 4, 5836-5845	7.8	2
63	High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse. *British Journal of Haematology*, **2021**, 195, 283-286	4.5	2
62	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. *Blood Cancer Discovery*,OF1-OF12	7	2
61	Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3. *Blood*, **2014**, 124, 3409-3409	2.2	1

60	Minimal Residual Disease (MRD) in Myeloma: Independent Outcome Prediction and Sequential Survival Benefits per Log Tumour Reduction. *Blood*, **2014**, 124, 3416-3416	2.2	1
59	The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma. *Blood*, **2015**, 126, 1806-1806	2.2	1
58	Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines. *Blood*, **2015**, 126, 1808-1808	2.2	1
57	Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM). *Blood*, **2015**, 126, 1843-1843	2.2	1
56	Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases. *Blood*, **2015**, 126, 1847-1847	2.2	1
55	Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations. *Blood*, **2015**, 126, 369-369	2.2	1
54	The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM. *Blood*, **2015**, 126, 372-372	2.2	1
53	Signatures of Mesenchymal Cell Lineages and Microenvironment Factors Are Dysregulated in High Risk Myeloma. *Blood*, **2016**, 128, 2065-2065	2.2	1
52	Myeloma-Derived Exosomes and Soluble Factors Suppress Natural Killer Cell Function. *Blood*, **2016**, 128, 2066-2066	2.2	1
51	Concurrent Amplification of MYC and 1q21 in Multiple Myeloma: Focal and Segmental Jumping Translocations of MYC. *Blood*, **2016**, 128, 3266-3266	2.2	1
50	Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma. *Blood*, **2016**, 128, 377-377	2.2	1
49	DNA Methylation Profiling of Myeloma Trial Patients Reveals Specific Epigenetic Changes Associated with Outcome. *Blood*, **2016**, 128, 804-804	2.2	1
48	Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results.. *Journal of Clinical Oncology*, **2012**, 30, 8015-8015	2.2	1
47	Loss of heterozygosity in multiple myeloma: A role for PARP inhibition?. *Journal of Clinical Oncology* , **2017**, 35, 8026-8026	2.2	1
46	Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 380	12.8	1
45	Identification of Biomarkers Associated with MAF-Mediated Resistance to Proteasome Inhibitors in t(14;16) Multiple Myeloma. *Blood*, **2015**, 126, 3020-3020	2.2	1
44	A Survey of Fusion Genes in Myeloma Identifies Kinase Domain Activation Which Could be Targeted with Available Treatments. *Blood*, **2016**, 128, 117-117	2.2	1
43	Title: Progression-Free Survival 2 in Hematological Cancer Treatment Choices: Challenges to Routine Use. *Blood*, **2016**, 128, 5982-5982	2.2	1

42	Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 667-675	2	1
41	FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. *Bone*, **2019**, 121, 134-138	4.7	1
40	Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM). *Blood*, **2014**, 124, 2128-2128	2.2	0
39	The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact. *Blood*, **2014**, 124, 2194-2194	2.2	0
38	Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment. *Blood*, **2021**, 138, 820-820	2.2	0
37	Hispanic or Latin American Ancestry Is Associated with a Similar Genomic Profile and a Trend Toward Inferior Outcomes in Newly Diagnosed Multiple Myeloma As Compared to Non-Hispanic White Patients in the Multiple Myeloma Research Foundation (MMRF) CoMMpassstudy. *Blood*, **2021**, 138, 4117-4117	2.2	0
36	High Risk Myeloma Is Characterized By the Bi-Allelic Inactivation of CDKN2C and RB1. *Blood*, **2016**, 128, 4416-4416	2.2	0
35	Rigosertib, a Pan RAS Inhibitor, Decreases Mouse and Human Myeloma Cell Growth in Preclinical Models. *Blood*, **2016**, 128, 5664-5664	2.2	0
34	MYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over-Expression and Decreased Overall Survival. *Blood*, **2013**, 122, 274-274	2.2	0
33	From Bench to Bedside: The Evolution of Genomics and Its Implications for the Current and Future Management of Multiple Myeloma. *Cancer Journal (Sudbury, Mass.)*, **2021**, 27, 213-221	2.2	0
32	An Enlarging Lung Nodule in an Immunocompromised Host. *Clinical Infectious Diseases*, **2018**, 66, 978-979	11.6	
31	Global Expression Changes of Malignant Plasma Cells over Time Reveals the Evolutionary Development of Signatures of Aggressive Clinical Behavior. *Blood*, **2018**, 132, 4457-4457	2.2	
30	Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53. *Blood*, **2018**, 132, 4441-4441	2.2	
29	Sequential Improvements in the Outcome of Autologous Stem Cell Transplantation for Multiple Myeloma over Time. *Blood*, **2018**, 132, 3168-3168	2.2	
28	Myeloma Patient-Derived Bone Marrow Serum Negatively Regulates Natural Killer Cell Activity. *Blood*, **2018**, 132, 4468-4468	2.2	
27	Global 3D-Epigenetic Dysregulation of Cyclin D1 and D2 Actively Controls Their Expression Pattern in Multiple Myeloma. *Blood*, **2018**, 132, 3904-3904	2.2	
26	Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma. *Blood*, **2018**, 132, 3185-3185	2.2	
25	Lack of a Spleen Signal on Diffusion Weighted MRI Is Associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma. *Blood*, **2018**, 132, 4471-4471	2.2	

24	Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials. *Blood*, **2018**, 132, 2000-2000	2.2
23	Mutant KRAS and Brafs Upregulate Stress Granules and Mediate Drug Resistance, Which Can be Modulated By Cox2 Inhibition in Multiple Myeloma. *Blood*, **2018**, 132, 3166-3166	2.2
22	Maximizing Pre-Transplant Response Is Associated with Improved Outcome for Myeloma Patients: Exploratory Analysis of the Myeloma XI Trial. *Blood*, **2018**, 132, 3280-3280	2.2
21	Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma. *Blood*, **2014** , 124, 2079-2079	2.2
20	PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients. *Blood*, **2014**, 124, 3407-3407	2.2
19	High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation. *Blood*, **2014**, 124, 2189-2189	2.2
18	Mafb Protein Confers Primary Resistance of Myeloma to Proteasome Inhibitors. *Blood*, **2014**, 124, 2091-2091	2.2
17	Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma. *Blood*, **2014**, 124, 723-723	2.2
16	Assessment of Total Lesion Glycolysis and Metabolic Tumor Volume Improve the Clinical Value of Focal Lesion Assessment By FDG PET/CT in Myeloma. *Blood*, **2015**, 126, 724-724	2.2
15	Molecular Subtyping and Risk Stratification for the Classification of Myeloma. *Blood*, **2015**, 126, 4173-4173	2.2
14	A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant. *Blood*, **2015**, 126, 3181-3181	2.2
13	Identifying Targets for Therapy in High Risk t(4;14) Myeloma Using Multi-Level Molecular and Phenotypic Analysis of Isogenic MMSET and MMSET Knock out Cell Lines. *Blood*, **2015**, 126, 1792-1792	2.2
12	Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. *Blood*, **2015**, 126, 3182-3182	2.2
11	Extending Metronomic Therapy to 28 Days (metro28) for Relapsed Refractory Multiple Myeloma (RRMM). *Blood*, **2015**, 126, 5395-5395	2.2
10	Velcade, Vorinostat and Dexamethasone (V2 D) in Relapsed Myeloma: Results of the Phase 2 Muk Four Trial. *Blood*, **2015**, 126, 1852-1852	2.2
9	Re-Mineralization of Large Pelvic Lytic Lesions By CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience. *Blood*, **2015**, 126, 4193-4193	2.2
8	Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma. *Blood*, **2015**, 126, 1777-1777	2.2
7	Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma. *Blood*, **2016**, 128, 2064-2064	2.2

6	The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States. *Blood*, **2016**, 128, 4438-4438	2.2
5	Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study. *Blood*, **2016**, 128, 5681-5681	2.2
4	Base-Pair Resolution Mapping of IGH Translocations in Multiple Myeloma Using Targeted Capture and Massively Parallel Sequencing. *Blood*, **2012**, 120, 3490-3490	2.2
3	A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM). *Blood*, **2013**, 122, 1967-1967	2.2
2	Single-Cell Genetic Analysis Reveals The Genetic Composition Of Founder Clones, Phylogenetic Patterns Of Branching and Parallel Evolution, and Clonal Fluctuations Following Patient Treatment In Multiple Myeloma. *Blood*, **2013**, 122, 398-398	2.2
1	HealthTree Cure Hub: A Patient-Derived, Patient-Driven Clinical Cancer Information Platform Used to Overcome Hurdles and Accelerate Research in Multiple Myeloma.. *JCO Clinical Cancer Informatics* , **2022**, 6, e2100141	5.2